BBA
ADCT icon

Baker Bros. Advisors’s ADC Therapeutics ADCT Stock Holding History

Baker Bros. Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,418,107
Closed -$34.5M – 123
2021
Q2 		$34.5M Hold
1,418,107
– – 0.15% 50
2021
Q1 		$34.6M Hold
1,418,107
– – 0.15% 53
2020
Q4 		$45.4M Sell
1,418,107
-269,393
-16% -$8.83M 0.17% 36
2020
Q3 		$55.7M Hold
1,687,500
– – 0.22% 28
2020
Q2 		$79M Buy
+1,687,500
New +$64M 0.35% 24

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Baker Bros. Advisors's ADCT Position: Q3 2021 in Review

Baker Bros. Advisors sold out of ADC Therapeutics (ADCT) in Q3 2021, closing a stake of 1,418,107 shares — an estimated $34.5M sold.

Baker Bros. Advisors first reported a position in ADCT in Q2 2020 and held it in 5 quarters. The position peaked at $79M in Q2 2020. 53 funds tracked by Wall St. Rank hold ADCT as of Q3 2021.

  • Baker Bros. Advisors reported no remaining ADC Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,418,107 ADC Therapeutics shares in Q3 2021, an estimated $34.5M.
  • Baker Bros. Advisors first reported a position in ADC Therapeutics in Q2 2020 and held it in 5 quarters.
  • Baker Bros. Advisors's ADC Therapeutics position peaked at $79M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2021.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.